Christoph Driessen

11.4k total citations · 1 hit paper
144 papers, 5.8k citations indexed

About

Christoph Driessen is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Christoph Driessen has authored 144 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 54 papers in Hematology and 48 papers in Oncology. Recurrent topics in Christoph Driessen's work include Multiple Myeloma Research and Treatments (50 papers), Ubiquitin and proteasome pathways (39 papers) and Peptidase Inhibition and Analysis (28 papers). Christoph Driessen is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Ubiquitin and proteasome pathways (39 papers) and Peptidase Inhibition and Analysis (28 papers). Christoph Driessen collaborates with scholars based in Switzerland, Germany and Netherlands. Christoph Driessen's co-authors include Marianne Kraus, Herman S. Overkleeft, Hubert Kalbacher, Hidde L. Ploegh, Lothar Rink, Michael Reich, Harold A. Chapman, Guo‐Ping Shi, Ana‐Maria Lennon‐Duménil and Ekkehard Weber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Investigation.

In The Last Decade

Christoph Driessen

131 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins

2005 504 citations Jörn Dengjel, Oliver Schoor et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Christoph Driessen

Since Specialization

Citations

This map shows the geographic impact of Christoph Driessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Driessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Driessen more than expected).

Fields of papers citing papers by Christoph Driessen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Driessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Driessen. The network helps show where Christoph Driessen may publish in the future.

Co-authorship network of co-authors of Christoph Driessen

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Driessen. A scholar is included among the top collaborators of Christoph Driessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Driessen. Christoph Driessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting proteostasis in multiple myeloma through inhibition of LTK 2025 ·Leukemia ·Thea Kristin Våtsveen, (unknown), (unknown), (unknown), Andrej Bešše, (unknown), Sigrid S. Skånland, Anders Tveita, (unknown), (unknown), Kristine Misund, Veronika Reiterer, (unknown), Christoph Driessen, Lenka Bešše, Kjetil Taskén, Fredrik Schjesvold, Hesso Farhan, Ludvig A. Munthe	1
2	HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer 2024 ·British Journal of Cancer ·(unknown), Lenka Sedlaříková, (unknown), Marianne Kraus, (unknown), Nicol Straková, Karel Souček, Jiří Navrátil, (unknown), Alana L. Welm, Markus Joerger, Christoph Driessen, Lenka Bešše	2
3	The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma 2023 ·Scientific Reports ·Lenka Bešše, Marianne Kraus, Andrej Bešše, Christoph Driessen, Ignazio Tarantino	5
4	Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma 2023 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tobias Schulze, Piero Giansanti, Lenka Bešše, Christoph Driessen, Angela M. Krackhardt, Bernhard Küster, Florian Bassermann	3
5	Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial 2023 ·BMJ Open ·(unknown), (unknown), Marc Schlaeppi, (unknown), Stephanie Roll, Petra Voiß, Jürgen Barth, Christoph Driessen, Claudia M. Witt	2
6	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma 2019 ·Blood Advances ·Yu-Hsiu T. Lin, Gregory P. Way, Benjamin G. Barwick, (unknown), (unknown), Ian Ferguson, Christoph Driessen, Lawrence Boise, Casey S. Greene, Arun P. Wiita	14
7	Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma 2019 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Daniela Brünnert, Marianne Kraus, Thorsten Stühmer, (unknown), (unknown), Pankaj Goyal, Christoph Driessen, Ralf C. Bargou, Manik Chatterjee	13
8	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 2019 ·Cancers ·Nicola Amodio, Maria Eugenia Gallo Cantafio, Cirino Botta, Valter Agosti, Cinzia Federico, Daniele Caracciolo, Domenica Ronchetti, Marco Rossi, Christoph Driessen, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone	35
9	Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits 2019 ·Journal of Medicinal Chemistry ·Bo‐Tao Xin, E.M. Huber, Gerjan de Bruin, Wolfgang Heinemeyer, Elmer Maurits, (unknown), Yimeng Du, (unknown), (unknown), Alexei F. Kisselev, Bogdan I. Florea, Christoph Driessen, Gijsbert A. van der Marel, M. Groll, Herman S. Overkleeft	28
10	Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion 2017 ·Blood ·Andrej Bešše, Lenka Bešše, Sara Christina Stolze, Marianne Kraus, (unknown), Herman S. Overkleeft, Christoph Driessen	1
11	Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus ( HIV )‐protease inhibitors lopinavir or nelfinavir 2017 ·British Journal of Urology ·Dominik Abt, Andrej Bešše, Lenka Sedlaříková, Marianne Kraus, (unknown), Tobias Silzle, (unknown), Ondřej Slabý, Hans‐Peter Schmid, Daniel Engeler, Christoph Driessen, Lenka Bešše	11
12	MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE 2015 ·Haematologica ·Kwee Yong, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez‐McQuire, Lionel Karlin, M.V. Mateos, Marc‐Steffen Raab, (unknown), Michèle Cavo	1
13	MULTIPLE MYELOMA MANAGEMENT: PRACTICE PATTERNS ACROSS EUROPE 2015 ·Haematologica ·Marc‐Steffen Raab, Michèle Cavo, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez‐McQuire, Lionel Karlin, M.V. Mateos, (unknown), Kwee Yong	3
14	Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events 2011 ·Clinical Cancer Research ·Shirin Arastu‐Kapur, Janet L. Anderl, Marianne Kraus, Francesco Parlati, Kevin D. Shenk, Sang Hyuck Lee, Tony Muchamuel, Mark K. Bennett, Christoph Driessen, Andrew J. Ball, Christopher J. Kirk	329
15	Cathepsin G is differentially expressed in primary human antigen-presenting cells 2008 ·Cellular Immunology ·Christina Stoeckle, (unknown), Eleni Adamopoulou, (unknown), Stephan Schiekofer, Arthur Melms, Ekkehard Weber, Christoph Driessen, Bernhard O. Boehm, Eva Tolosa, Timo Burster	23
16	A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A 2007 ·Biochemical and Biophysical Research Communications ·Nousheen Zaidi, Timo Burster, (unknown), (unknown), Bernhard O. Boehm, Christoph Driessen, Wolfgang Voelter, Hubert Kalbacher	31
17	Autophagy promotes MHC class II presentation of peptides from intracellular source proteins breakdown → 2005 ·Proceedings of the National Academy of Sciences ·Jörn Dengjel, Oliver Schoor, Rainer Fischer, Michael Reich, Marianne Kraus, Margret Müller, Katharina Kreymborg, Florian Altenberend, Jens Brandenburg, Hubert Kalbacher, Roland Brock, Christoph Driessen, Hans‐Georg Rammensee, Stefan Stevanović	504
18	Differential Processing of Autoantigens in Lysosomes from Human Monocyte-Derived and Peripheral Blood Dendritic Cells 2005 ·The Journal of Immunology ·Timo Burster, Alexander Beck, Eva Tolosa, Petra Schnorrer, Robert Weissert, Michael Reich, Marianne Kraus, Hubert Kalbacher, Hans‐Ulrich Häring, Ekkehard Weber, Herman S. Overkleeft, Christoph Driessen	41
19	Cathepsin G, and Not the Asparagine-Specific Endoprotease, Controls the Processing of Myelin Basic Protein in Lysosomes from Human B Lymphocytes 2004 ·The Journal of Immunology ·Timo Burster, Alexander Beck, Eva Tolosa, Viviana Marin‐Esteban, Olaf Rötzschke, Kirsten Falk, Alfred Lautwein, Michael Reich, Jens Brandenburg, Gerold Schwarz, Heinz Wiendl, Arthur Melms, Rainer Lehmann, Stefan Stevanović, Hubert Kalbacher, Christoph Driessen	63
20	Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis 2003 ·Journal of Clinical Investigation ·Eva Tolosa, Weijie Li, Yoshiyuki Yasuda, Wolfgang Wienhold, Lisa Denzin, Alfred Lautwein, Christoph Driessen, Petra Schnorrer, Ekkehard Weber, Stefan Stevanović, Raffael Kurek, Arthur Melms, Dieter Brömme	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact